<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJPN</journal-id><journal-title-group><journal-title>International Journal of Psychiatry and Neurology</journal-title></journal-title-group><issn pub-type="epub">2166-5788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/IJPN.2019.82003</article-id><article-id pub-id-type="publisher-id">IJPN-30151</article-id><article-categories><subj-group subj-group-type="heading"><subject>IJPN20190200000_13708653.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  经颅磁刺激联合认知疗法治疗卒中后抑郁的疗效分析
   Therapeutic Effect of Transcranial Magnetic Stimulation Combined with Cognitive Therapy on Post-Stroke Depression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>军祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>梦园</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>05</month><year>2019</year></pub-date><volume>08</volume><issue>02</issue><fpage>13</fpage><lpage>18</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探究经颅磁刺激联合认知疗法治疗卒中后抑郁(post stroke depression PSD)的疗效。方法：选取延大附院神经内科确诊为卒中后抑郁的患者82例分为实验组和对照组，对照组给予常规治疗 + 
   认知疗法，实验组给予常规治疗 
   + 
   认知疗法 
   + 
   经颅重复磁刺激(Repetitive transcranial magnetic stimulation rTMS)，分别于初次治疗时、第4周采用美国国立卫生院脑卒中量表(NIHSS)、汉密顿抑郁量表(Hamilton Depression Scale, HAMD)、蒙哥马利抑郁评定量表(Montgomery Asberg Depression Rating Scale MADRS)和改良Rankin量表(mRS)进行综合分析评估神经功能恢复、抑郁改善情况。结果：参与82例卒中后抑郁患者有2人因依从性差退出实验，随着进程随访评估完成了98%，各量表依基线水平治疗4周后HAMD和MADRS抑郁评分值明显低于对照组(tHADM = 19.37**, p &lt; 0.05, tMADRE = 25.23, p &lt; 0.05)，于治疗4周后NIHSS和mRS神经功能恢复评分因子显著低于对照组(tNIHSS = 11.39**, p &lt; 0.05, tmRS = 4.13*, p &lt; 0.05)。结论：采用经颅磁刺激联合认知疗法治疗卒中后抑郁发现，rTMS联合认知疗法有助于患者神经功能恢复，改善抑郁状况，降低住院率、致残率，提高患者生活及社会参与度。 Objective: To investigate the efficacy of transcranial magnetic stimulation combined with cognitive therapy in the treatment of post stroke depression (PSD). Methods: Eighty-two patients with post-stroke depression diagnosed by the Department of Neurology of Yanda Affiliated Hospital were divided into experimental group and control group. The control group received conventional therapy + cognitive therapy. The experimental group received conventional therapy + cognitive therapy + transcranial repetitive magnetic stimulation (Repetitive transcranial magnetic stimulation rTMS). National institutes of health stroke scale (NIHSS), Hamilton Depression Scale (HAMD), Montgomery Asberg Depression Rating Scale MADRS and modified Rankin Scale (mRS) were used for comprehensive analysis and evaluation of neurological function recovery and depression improvement at the first treatment and the fourth week respectively. Results: Two of the 82 post-stroke depression patients withdrew from the study due to poor compliance. 98% of the patients were followed up by the follow-up evaluation. The HAMD and MADRS depression scores were significantly lower than the control group after 4 weeks of treatment (tHADM = 19.37**, p &lt; 0.05, tMADRE = 25.23, p &lt; 0.05), the NIHSS and mRS neurological recovery scoring factors were significantly lower than the control group after 4 weeks of treatment (tNIHSS = 11.39**, p &lt; 0.05, tmRS = 4.13*, p &lt; 0.05). Conclusion: Using transcranial magnetic stimulation combined with cognitive therapy to treat post-stroke depression, rTMS combined with cognitive therapy can help patients with neurological recovery, improve depression, reduce hospitalization rate, disability rate, and improve patient life and social participation. 
  
 
</p></abstract><kwd-group><kwd>认知疗法，经颅重复磁刺激，脑卒中，抑郁,  Cognitive Therapy</kwd><kwd> Transcranial Repetitive Magnetic Stimulation</kwd><kwd> Stroke</kwd><kwd> Depression</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>经颅磁刺激联合认知疗法治疗卒中后 抑郁的疗效分析<sup> </sup></title><p>武军祥，李梦园，刘杰</p><p>延安大学附属医院，陕西 延安</p><p><img src="//html.hanspub.org/file/2-2240109x1_hanspub.png" /></p><p>收稿日期：2019年4月22日；录用日期：2019年5月3日；发布日期：2019年5月10日</p><disp-formula id="hanspub.30151-formula19"><graphic xlink:href="//html.hanspub.org/file/2-2240109x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探究经颅磁刺激联合认知疗法治疗卒中后抑郁(post stroke depression PSD)的疗效。方法：选取延大附院神经内科确诊为卒中后抑郁的患者82例分为实验组和对照组，对照组给予常规治疗 + 认知疗法，实验组给予常规治疗 + 认知疗法 + 经颅重复磁刺激(Repetitive transcranial magnetic stimulation rTMS)，分别于初次治疗时、第4周采用美国国立卫生院脑卒中量表(NIHSS)、汉密顿抑郁量表(Hamilton Depression Scale, HAMD)、蒙哥马利抑郁评定量表(Montgomery Asberg Depression Rating Scale MADRS)和改良Rankin量表(mRS)进行综合分析评估神经功能恢复、抑郁改善情况。结果：参与82例卒中后抑郁患者有2人因依从性差退出实验，随着进程随访评估完成了98%，各量表依基线水平治疗4周后HAMD和MADRS抑郁评分值明显低于对照组(tHADM = 19.37**, p &lt; 0.05, tMADRE = 25.23, p &lt; 0.05)，于治疗4周后NIHSS和mRS神经功能恢复评分因子显著低于对照组(tNIHSS = 11.39**, p &lt; 0.05, tmRS = 4.13*, p &lt; 0.05)。结论：采用经颅磁刺激联合认知疗法治疗卒中后抑郁发现，rTMS联合认知疗法有助于患者神经功能恢复，改善抑郁状况，降低住院率、致残率，提高患者生活及社会参与度。</p><p>关键词 :认知疗法，经颅重复磁刺激，脑卒中，抑郁</p><disp-formula id="hanspub.30151-formula20"><graphic xlink:href="//html.hanspub.org/file/2-2240109x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2240109x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-2240109x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>众所周知，全球老龄化仍旧居高不下，而心脑血管疾病主要罹患于中老年人，且不容小觑的是脑血管疾病已向年轻化迁移，据Feigin指出脑卒中的发病率、流行率、死亡率、新复发率和残疾调整后的寿命年率有下降趋势，其主要归因于全球卒中疾病三级预防有力推荐 [<xref ref-type="bibr" rid="hanspub.30151-ref1">1</xref>] ，然而，据MEJM分析指出中国脑中风发病率和死亡率居世界第一，且风险最高，每5个人中就会有2人罹患卒中 [<xref ref-type="bibr" rid="hanspub.30151-ref2">2</xref>] 。这不仅警示临床工作从病因学上探究深入，而且尚需知晓卒中终生风险可能有助于预防和宣传教育。</p><p>卒中后抑郁(PSD)是脑血管事件后常见并发症之一，且发病率呈上升趋势，Robinson研究发现脑卒中后抑郁第一年发生率约为30%~35%，且高峰集中于发病半年内 [<xref ref-type="bibr" rid="hanspub.30151-ref3">3</xref>] 。PSD主要为持久且显著的心境低落的临床表现，延缓患者神经功能恢复，降低患者生命及生存质量，甚至造成自杀。认知疗法可对不良心理精神预防干预，有助于提高患者正性情绪，降低抑郁、焦虑等负面影响。由Wang等荟萃分析得出，认知疗法单独和辅助认知疗法都有益于改善PSD后抑郁症状 [<xref ref-type="bibr" rid="hanspub.30151-ref4">4</xref>] 。重复经颅磁刺激(rTMS)是一种安全、无创伤、无疼痛的新型治疗技术，对治疗心境障碍、帕金森等疾病，取得较好成果。且经美国FDA批准认证，rTMS为一种新型抗抑郁方法 [<xref ref-type="bibr" rid="hanspub.30151-ref5">5</xref>] 。抗抑郁药物在某种程度上降低患者依从性，增加其心理负担，而认知疗法和rTMS作为非药物治疗手段可改善上述情况，本文旨在从对卒中后抑郁患者早期阶段通过非药物手段干预预防，研究其对PSD患者神经功能、心境障碍、生活治疗改变，来了解其效果。</p></sec><sec id="s4"><title>2. 研究资料</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取我院2018年1月1日至2018年12月31日就诊于我院病确诊为卒中后抑郁的患者80例，以就诊先后顺序采用EXCEL随机函数分为实验组和对照组。实验组40例(女性33例，男性7例，脑梗死31例，脑出血9例)对照组40例(女性29例，男性11例，脑梗死34例，脑出血6例)。文化及工作背景中：中专以上学历37例，中专以下43例(初中18例，小学11例，文盲14例)。一般资料基本情况见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information of the two groups of patients included in the stud</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男/女(例)</th><th align="center" valign="middle" >年龄( x &#175; &#177; s )</th><th align="center" valign="middle" >病程(月 x &#175; &#177; s )</th><th align="center" valign="middle" >卒中类型</th></tr></thead><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >7/33</td><td align="center" valign="middle" >58.30 &#177; 11.90</td><td align="center" valign="middle" >12.22 &#177; 4.50</td><td align="center" valign="middle" >缺血/出血31/9</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >11/29</td><td align="center" valign="middle" >66.10 &#177; 8.74</td><td align="center" valign="middle" >14.12 &#177; 5.90</td><td align="center" valign="middle" >缺血/出血34/6</td></tr></tbody></table></table-wrap><p>表1. 两组患者纳入研究者一般资料</p></sec><sec id="s4_2"><title>2.2. 纳入标准和排出标准</title><p>纳入标准：1) 符合脑卒中诊断标准，并经头颅CT和MRI证实 [<xref ref-type="bibr" rid="hanspub.30151-ref6">6</xref>]；2) 符合国际疾病分类法ICD-10中抑郁症的诊断标准 [<xref ref-type="bibr" rid="hanspub.30151-ref7">7</xref>]；3) 年龄40~85周岁，首次发病；4) 病情稳定，依从性好，能完成配合；5) 遵循患者及家属自愿。排除标准：1) 不符合脑卒中诊断标准；2) 卒中前患有抑郁症；3) 复发性卒中；4) 心、肺、肝、肾功能不全和恶性高血压等其他限制活动的并发症；5) 存在严重认知及交流障碍无法配合者；6) 存在脑肿瘤等其他脑器质性疾病及既往精神异常者。</p></sec><sec id="s4_3"><title>2.3. 研究方法</title><p>两组患者予常规脑卒中治疗(缺血性卒中给予抗血小板聚集、控制血压、控制血糖等治疗，出血性卒中给予脱水降颅压、调整血压、防止继续出血等治疗)；认知疗法内容：1) 了解患者抑郁程度和心境及情绪表现，建议融洽信任医患关系；2) 给予患者宣讲不利情绪表现，以及其带来的负面影响，可能的原因和校正的方法，促使其行为和认识趋向现实；3) 通过专业和非专业信念帮助患者克服负性情绪，改变其防御行为，同时启发患者树立正确的思维模式，重塑人格和认为；4) 鼓励患者参与娱乐活动，树立兴趣和爱好，鼓励家人参与，形成共同参与模式，促其建立信念，每周1次，持续时间为1小时，总周期为4周。对照组：给予常规卒中治疗基础上 + 认知疗法；实验组：给予常规卒中治疗基础上 + 认知疗法 + rTMS (南京伟思magneuro60)，每次1200个脉冲，20个序列，连续刺激15 min/次，qd，部位选取右侧前额叶背外侧皮质，共4周。</p></sec><sec id="s4_4"><title>2.4. 评定内容</title><p>为避免混杂因素采取双盲发，量表由单一人员(不参与分组、治疗及统计)进行，于治疗前和第4周采用汉密尔顿抑郁量表HAMD和MADRS评定抑郁程度，以HAMD为主评基线，低于7分无抑郁症状，超过17分为轻或中度抑郁，超过24分为严重抑郁；采用NIHSS和mRS进行神经功能评定，以NIHSS为主评基线，评分越低，神经功能恢复越好。疗效评定采用HAMD评分，分为痊愈、显著有效、有效和无效，总有效率 = (痊愈 + 显效 + 好转)/总例数 &#215; 100%。</p></sec><sec id="s4_5"><title>2.5. 统计方法</title><p>对本研究数据为连续性计量资料，采用Kolmogorov-Smirnov检验，服从正态分布，计量资料用均数&#177; 标准差(x &#177; s)表示，进行配对样本t检验，鉴于评分高具有意义，以采用单侧p &lt; 0.05，表示差异有统计学意义，p &lt; 0.01表示差异具有显著性统计意义，二分类数据采用卡方检验，p &lt; 0.05，表示差异有统计学意义，所有统计分析均采用STATA15.0软件实现。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组疗效比较</title><p>治疗4周末，研究组痊愈22例，显效11例，好转4例，无效3例，总有效率92.5%，对照组痊愈18例，显效9例，好转9例，无效4例，总有效率90%，两组有效率差异有统计学意义(χ<sup>2</sup> = 9.44**, p &lt; 0.05)。见表2。</p></sec><sec id="s5_2"><title>3.2. 神经功能及抑郁评定</title><p>治疗前两组患者各因子间均无统计学意义，于治疗4周后HAMD和MADRS抑郁评分值明显低于对照组(tHADM = 19.37**, p &lt; 0.05, tMADRE = 25.23, p &lt; 0.05)，于治疗4周后NIHSS和mRS神经功能恢复评分因子显著低于对照组(tNIHSSS = 11.39, p &lt; 0.05, tmRS = 4.13, p &lt; 0.05)，余组间无统计学意义。见表3、表4。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Effectiveness of two groups of patients after treatment (%</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  colspan="4"  >疗效程度</th><th align="center" valign="middle"  rowspan="2"  >总有效率</th></tr></thead><tr><td align="center" valign="middle" >痊愈</td><td align="center" valign="middle" >显著有效</td><td align="center" valign="middle" >有效</td><td align="center" valign="middle" >无效</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >22 (55%)</td><td align="center" valign="middle" >11 (27.5%)</td><td align="center" valign="middle" >4 (10%)</td><td align="center" valign="middle" >3 (7.5%)</td><td align="center" valign="middle" >92.5%</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >18 (45%)</td><td align="center" valign="middle" >9 (22.5%)</td><td align="center" valign="middle" >9 (22.5%)</td><td align="center" valign="middle" >4 (10%)</td><td align="center" valign="middle" >90%</td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗后的有效率(%)</p><p>注：两组间比较**p &lt; 0.01。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The scores of HAMD and MADRS scores of depression in the two groups ( x &#175; &#177; s points</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >样本(例)</th><th align="center" valign="middle" >初始值</th><th align="center" valign="middle" >4周值</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="6"  >HAMD评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >15.25 &#177; 2.92</td><td align="center" valign="middle" >6.42 &#177; 3.30</td><td align="center" valign="middle" >19.37<sup>**</sup></td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >14.42 &#177; 3.10</td><td align="center" valign="middle" >8.32 &#177; 2.10</td><td align="center" valign="middle" >17.05</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle"  colspan="6"  >MADRS评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >18.82 &#177; 2.12</td><td align="center" valign="middle" >10.30 &#177; 1.57</td><td align="center" valign="middle" >25.23</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >19.50 &#177; 2.23</td><td align="center" valign="middle" >11.65 &#177; 2.80</td><td align="center" valign="middle" >15.44</td><td align="center" valign="middle" >p &lt; 0.05</td></tr></tbody></table></table-wrap><p>表3. 两组患者抑郁程度HAMD和MADRS评分情况( x &#175; &#177; s 分)</p><p>注：两组间比较**p &lt; 0.01。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> NIHSS and mRS scores of depression in the two groups ( x &#175; &#177; s points</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >样本(例)</th><th align="center" valign="middle" >初始值</th><th align="center" valign="middle" >4周值</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="6"  >NIHSS评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >11.72 &#177; 2.92</td><td align="center" valign="middle" >6.4 &#177; 2.11</td><td align="center" valign="middle" >11.39</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >11.67 &#177; 2.71</td><td align="center" valign="middle" >6.60 &#177; 1.82</td><td align="center" valign="middle" >15.42</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle"  colspan="6"  >mRS评分</td></tr><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >2.57 &#177; 0.71</td><td align="center" valign="middle" >1.82 &#177; 0.93</td><td align="center" valign="middle" >4.13</td><td align="center" valign="middle" >p &lt; 0.05</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >2.95 &#177; 0.87</td><td align="center" valign="middle" >1.70 &#177; 0.88</td><td align="center" valign="middle" >7.86</td><td align="center" valign="middle" >p &lt; 0.05</td></tr></tbody></table></table-wrap><p>表4. 两组患者抑郁程度NIHSS和mRS评分情况( x &#175; &#177; s 分)</p><p>注：两组间比较**p &lt; 0.01。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>5-HT羟色胺能神经元和肾上腺素能神经元在抑郁水平中发挥重要作用，其神经递质降低易导致抑郁诱发，其5-羟色胺能在睡眠、食欲以及情绪等生理活动调节中起重要作用，Żmudzka等综述描述突触后5-HT1A，5-HT1B，5-HT2B和5-HT4受体或突触前5-的阻断HT1A，突触前5-HT1B，5-HT2A，5-HT3，5-HT5A和5-HT7可能导致抗抑郁样作用，而对于5-HT2C和5-HT6亚型阻滞和激活均诱导抗抑郁样活性，尚待进一步探究 [<xref ref-type="bibr" rid="hanspub.30151-ref8">8</xref>] ，另者Han发现通过恢复海马CA1突触可塑性来改善抑郁样行为，其可能主要通过调节5-HT受体水平来介导 [<xref ref-type="bibr" rid="hanspub.30151-ref9">9</xref>] 。目前还发现与应急、神经改变、免疫–炎症以及病毒有关 [<xref ref-type="bibr" rid="hanspub.30151-ref9">9</xref>] 。卒中后抑郁为脑血管事件损害上述通路导致神经递质水平改变诱发抑郁症状，还与家庭、社会因素有关。卒中后抑郁临床表现主要以兴趣减退、情绪低落、心境抑制以及精神焦虑等为主，重者有自杀倾向，其自知力相对保存完好。PSD不仅影响卒中后神经功能恢复而且严重影响患者社会生活质量。三环类抑郁药物、5-HT再摄取抑制剂等药物在治疗中发挥明显作用，但是其不良反应和社会因素增加患者心理负担，降低患者依从性。所以一些非药物治疗手段可发挥举足轻重的地位，Nguyen S指出认知疗法可改善卒中后疲劳，睡眠质量和抑郁等症状，可为一种有前途的治疗方法 [<xref ref-type="bibr" rid="hanspub.30151-ref10">10</xref>] 。而Raglio A发现音乐治疗评估在PSD中也可较好改善PSD [<xref ref-type="bibr" rid="hanspub.30151-ref11">11</xref>] 。据国外文献显示，rTMS能促进神经生理活动、神经纤维再生可塑以及递质水平，改善脑灌注，激活神经功能，助于脑组织康复，调节情绪正常化 [<xref ref-type="bibr" rid="hanspub.30151-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.30151-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.30151-ref14">14</xref>] 。</p><p>本研究对PSD患者实验组采用常规卒中治疗 + 认知疗法 + 经颅磁刺激方法，通过认知和磁激化作用促进患者神经功能恢复，降低患者负性信念，加强正性思维模式，从而改变患者对客观事件的情绪和行为反应，对照组上述情况明显低于实验组，p &lt; 0.05，差异具有统计学意义。非药物治疗手段可在发病初期或者提前给予预防干预，不用或减少药物服用，解除或降低药物不良反应和依赖性的同时促进神经功能恢复，肢体瘫痪康复，降低不良情绪负面影响，提升患者生存质量，降低住院率和致残率。当然此实验研究周期短，对于长期治疗中，患者依从性和试验疗效仍需进一步采取多中心双盲随机对照试验探讨分析，以求最合理方案提高患者治疗效果供临床医生较好的应用。</p></sec><sec id="s7"><title>文章引用</title><p>武军祥,李梦园,刘 杰. 经颅磁刺激联合认知疗法治疗卒中后抑郁的疗效分析 Therapeutic Effect of Transcranial Magnetic Stimulation Combined with Cognitive Therapy on Post-Stroke Depression[J]. 国际神经精神科学杂志, 2019, 08(02): 13-18. https://doi.org/10.12677/IJPN.2019.82003</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30151-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Feigin, V.L., Norrving, B. and Mensah, G.A. (2017) Global Burden of Stroke. Circulation Research, 120, 439-448.  
&lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.116.308413</mixed-citation></ref><ref id="hanspub.30151-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">The GBD 2016 Lifetime Risk of Stroke Collaborators (2018) Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. The New England Journal of Medicine; 379, 2429-2437.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa1804492</mixed-citation></ref><ref id="hanspub.30151-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, R.G. and Jorge, R.E. (2016) Post-Stroke Depression: A Review. American Journal of Psychiatry, 173, 221-231. &lt;br&gt;https://doi.org/10.1176/appi.ajp.2015.15030363</mixed-citation></ref><ref id="hanspub.30151-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S.B., Wang, Y.Y., Zhang, Q.E., et al. (2018) Cogni-tive Behavioral Therapy for Post-Stroke Depression: A Meta-Analysis. Journal of Affective Disorders, 235, 589-596. &lt;br&gt;https://doi.org/10.1016/j.jad.2018.04.011</mixed-citation></ref><ref id="hanspub.30151-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">O’Reardon, J.P., Solvason, H.B., Janicak, P.G., et al. (2007) Effi-cacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Ran-domized Controlled Trial. Biological Psychiatry, 62, 1208-1216. &lt;br&gt;https://doi.org/10.1016/j.biopsych.2007.01.018</mixed-citation></ref><ref id="hanspub.30151-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华神经科学会, 中华神经外科学会. 各类脑血管病诊断要点[J]. 中华神经科杂志, 1996, 29(6): 379-380.</mixed-citation></ref><ref id="hanspub.30151-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">范肖冬. ICD-10精神与行为障碍分类[J]. 北京: 人民卫生出版社, 1993: 70-79.</mixed-citation></ref><ref id="hanspub.30151-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zmudzka, E., Sałaciak, K., Sapa, J. and Pytka, K. (2018) Serotonin Receptors in Depression and Anxiety: Insights from Animal Studies. Life Sciences, 210, 106-124. &lt;br&gt;https://doi.org/10.1016/j.lfs.2018.08.050</mixed-citation></ref><ref id="hanspub.30151-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Villa, R.F., Ferrari, F. and Moretti, A. (2018) Post-Stroke Depression: Mechanisms and Pharmacological Treatment. Pharmacology &amp; Therapeutics, 184, 131-144. &lt;br&gt;https://doi.org/10.1016/j.pharmthera.2017.11.005</mixed-citation></ref><ref id="hanspub.30151-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Han, X., Wu, H., Yin, P., et al. (2018) Electroacupuncture Restores Hippocampal Synaptic Plasticity via Modulation of 5-HT Receptors in a Rat Model of Depression. Brain Re-search Bulletin, 139, 256-262.  
&lt;br&gt;https://doi.org/10.1016/j.brainresbull.2018.03.004</mixed-citation></ref><ref id="hanspub.30151-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, S., Wong, D., McKay, A., et al. (2019) Cognitive Behavioural Therapy for Post-Stroke Fatigue and Sleep Disturbance: A Pilot Randomised Controlled Trial with Blind Assessment. Neuropsychological Rehabilitation, 29, 723-738. &lt;br&gt;https://doi.org/10.1080/09602011.2017.1326945</mixed-citation></ref><ref id="hanspub.30151-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Raglio, A., Zaliani, A., Baiardi, P., et al. (2017) Active Music Therapy Approach for Stroke Patients in the Post-Acute Rehabilitation. Neurological Sciences, 38, 893-897. &lt;br&gt;https://doi.org/10.1007/s10072-017-2827-7</mixed-citation></ref><ref id="hanspub.30151-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nahas, Z., DeBrux, C., Chandler, V., et al. (2000) Lack of Sig-nificant Changes on Magnetic Resonance Scans before and after 2 Weeks of Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Depression. The Journal of ECT, 16, 380-390. &lt;br&gt;https://doi.org/10.1097/00124509-200012000-00008</mixed-citation></ref><ref id="hanspub.30151-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Michael, N., Gosling, M., Reutemann, M., et al. (2003) Metabolic Changes after Repetitive Transcranial Magnetic Stimulation (rTMS) of the Left Prefrontal Cortex: A Sham-Controlled Proton Magnetic Resonance Spectroscopy (1HMRS) Study of Healthy Brain. European Journal of Neuroscience, 17, 2462-2468.  
&lt;br&gt;https://doi.org/10.1046/j.1460-9568.2003.02683.x</mixed-citation></ref></ref-list></back></article>